Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Findings from a just-published study indicate that women who use the contraceptive injection depot medroxyprogesterone acetate (DMPA, marketed as Depo-Provera, Pfizer, New York City) appear to have a threefold increased risk of acquiring chlamydia and gonorrhea when compared to women not using a hormonal contraceptive.

New study eyes link to DMPA use, STD risk